107 results on '"Le Pechoux C"'
Search Results
2. OC-0611 Lungtech EORTC 22113-08113 prospective multicenter trial: SBRT for central lung tumors.
3. 48MO Characteristics and outcomes of 76 patients with pleomorphic liposarcoma: The Gustave Roussy experience
4. 145P Everolimus for the treatment of thymic epithelial tumors (TETs): A real-world experience
5. Durable response to crizotinib in metastatic angiomatoid fibrous histiocytoma with EWSR1–CREB1 fusion and ALK overexpression
6. PO-1246 Lung SBRT after pneumonectomy
7. PO-1053 cost-effectiveness of prophylactic cranial irradiation in stage III non-small cell lung cancer
8. Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials
9. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
10. 83P Association of lung immune prognostic index (LIPI) with progression-free survival (PFS) in soft-tissue sarcoma (STS) patients treated with immunotherapy (IO) in early phase trials
11. 1523MO Initial active surveillance strategy for patients with peripheral sporadic desmoids: A multicentre phase II observational trial
12. 1551P Efficacy of early phase trials for soft-tissue sarcoma patients: The Centre Léon Bérard and Gustave Roussy experience
13. Cancers bronchiques de stade III : rôle de l’onco-radiothérapeute
14. 1742TiP RADIORYTHMIC: Phase III, opened, randomized study of post-operative radiotherapy (PORT) versus surveillance in stage IIb/III of Masaoka Koga thymoma after complete surgical resection
15. 1170O An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Characterisation of PORT efficacy in lung ART (IFCT-0503, UK NCRI, SAKK)
16. 1344P Molecular features of young cannabis smokers with advanced non-small cell lung cancer (aNSCLC)
17. SP-0665 Multi-modality treatment of soft tissue sarcoma
18. MA08.04 LIPI and outcomes of durvalumab as consolidation therapy after ChRT in patients with locally-advanced NSCLC
19. SP-0146: Against the motion: This house believes that hippocampus avoiding WBI is the current standard of care
20. PH-0280: Quality of surgery and RT in stage IIIN2 NSCLC: Insights from the Lung Adjuvant Radiotherapy trial
21. OC-0457: Stereotactic body radiation therapy (SBRT) for oligometastatic soft tissue sarcoma (STS)
22. LBA84 Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: Results from the ETOP/IFCT 4-12 STIMULI trial
23. LBA3_PR An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Primary end-point analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683
24. Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts
25. Association of metastatic pattern and molecular status in metastatic lung non-small cell lung cancer adenocarcinomas
26. Cancers bronchiques localement avancés ou inopérables: rôle de l’oncologue
27. OA12.01 PCI for Radically Treated Non-Small Cell Lung Cancer: A Meta-Analysis Using Updated Individual Patient Data of Randomized Trials
28. MS07.06 Hot Topics in SBRT - Biopsy, Central Lesions, Radiologic Evaluation
29. P2.09-15 PD-L1 Expression and Lymphocyte Infiltration in Resected Stage IIIAN2 NSCLC: Preliminary Data from a Lung ART Ancillary Study
30. Cancers bronchiques de stade III: rôle de l’onco-radiothérapeute
31. Correction to: Surgery in reference centers improves survival of sarcoma patients: a nationwide study
32. Surgery in reference centers improves survival of sarcoma patients: a nationwide study
33. OC-0271 First randomized study of Hafnium nanoparticles activated by radiotherapy in soft tissue sarcoma
34. SP-0214 Update on the management of SCLC
35. OC-0061 EORTC 22113-8113 Lungtech trial on SBRT of central lung tumors
36. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)
37. Act.in.Sarc: An International Randomized Phase III Trial Evaluating Efficacy and Safety of First-in-Class NBTXR3 Hafnium Oxide Nanoparticles Activated By Preoperative Radiotherapy in Locally Advanced Soft Tissue Sarcoma
38. Exploratory Dosimetric Study of the Impact of the Pre-Radiation Therapy Intra Tumoral Injection of Hafnium Oxide Nanoparticles Along the Radiation Treatment of Extremity and Trunk Wall Soft Tissue Sarcomas
39. Radiation Therapy in Extracranial Chondrosarcomas: A Multicenter French Sarcoma Group and Rare Cancer Network Study
40. Hafnium Oxide Nanoparticles Activated By Radiation Therapy for the Treatment of Solid Tumors
41. OA13.05 Prophylactic Cranial Irradiation (PCI) for Limited-Stage Small-Cell Lung Cancer: Results from the Phase 3 CONVERT Trial
42. P1.01-19 Efficacy of Tyrosine Kinase Inhibitors in EGFR Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases
43. Prognostic factors in non-small cell lung cancer (NSCLC) patients (pts) with brain metastases (BM) treated with immune checkpoint inhibitors (ICI)
44. MA08.09 Impact of Brain Metastases in Immune Checkpoint Inhibitors (ICI) Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
45. Management of leptomeningeal metastases in EGFR mutated non-small cell lung cancer: Analysis of tyrosine kinase inhibitors sequence
46. Adriamycin and ifosfamide-based regimen as induction chemotherapy in desmoplastic small round cell tumors: Results of a retrospective single-center study on 34 patients
47. No benefit of preoperative chemotherapy for primary retroperitoneal sarcomas: Results from a single center propensity-matched analysis
48. P1.14-04 Stereotactic Body Radiation Therapy for Pleural Recurrences of Thymoma
49. P1.01-07 Immune-Related Pneumonitis in NSCLC Patients Treated with Immune Checkpoint Inhibitors (ICI): Impact of Previous Thoracic Radiotherapy
50. A phase II/III trial of hafnium oxide nanoparticles activated by radiotherapy in the treatment of locally advance soft tissue sarcoma of the extremity and trunk wall
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.